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Abstract
Background: Experimental autoimmune encephalomyelitis (EAE) is a mouse model of multiple sclerosis (MS).
It has been shown that Th17 cells are critical for EAE pathogenesis. Mice lacking CXCR3 develop aggravated EAE
compared with wild-type (WT) mice. This study investigated the effect of CXCR3 on Th17 expansion during EAE
and further addressed the underlying mechanism.
Methods: Both active EAE and adoptive-transfer EAE experiments were employed for studying EAE pathogenesis in
WT and CXCR3−/− mice. Demyelination and leukocyte infiltration in the spinal cord of mice were analyzed by luxol
fast blue staining and flow cytometry analysis, respectively. Glial cells expressing CXCR3 in the spinal cord were
analyzed by immunofluorescence staining. Cytokine and chemokine levels in the spinal cord were analyzed using
quantitative real-time PCR and enzyme-linked immunosorbent assay (ELISA). The glial cell line U87MG was
employed for studying the CXCR3 signaling-mediated mechanism regulating Th17 expansion.
Results: CXCR3−/− mice exhibited more severe EAE and had significantly increased central nervous system (CNS)-
infiltrating Th17 cells compared with WT mice. Adoptive-transfer experiments showed that CXCR3−/− recipient mice
that received Th17 cells polarized from splenocytes of myelin oligodendrocyte glycoprotein (MOG)-immunized
CXCR3−/− mice or MOG-immunized WT mice always developed more severe EAE and had significantly increased
CNS-infiltrating Th17 cells compared with WT recipient mice that received Th17 cells from the same origin.
Furthermore, during EAE, the number of activated glial cells was increased in the CNS of MOG-immunized
CXCR3−/− mice, and CXCR3-deficient glial cells expressed increased levels of cytokine genes required for Th17
expansion and recruitment. Finally, we found that extracellular signal-regulated kinase (ERK) activation elicited by
CXCR3 signaling in U87MG cells attenuated the activation of NF-κB, a key transcription factor critical for the
induction of IL-23 and CCL20, which are required for Th17 cell expansion and recruitment, respectively.
Conclusions: This study demonstrates a previously unrecognized role of CXCR3 signaling in glial cells in negatively
regulating Th17 cell expansion during EAE. Our results demonstrate that, in addition to its well-known role in the
recruitment of immune cells, CXCR3 in CNS glial cells plays a critical role in restraining the pro-Th17 cytokine/
chemokine milieu during EAE, thereby diminishing Th17 cell expansion in the CNS and suppressing disease
development.
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Background
Multiple sclerosis (MS) is a chronic demyelinating in-
flammatory disease of the central nervous system (CNS)
that leads to neurological impairment and, subsequently,
disability in the majority of patients [1]. A mouse model
of MS is the experimental autoimmune encephalomyeli-
tis (EAE) [2]. The pathogenesis of MS and EAE results
from infiltration of the CNS by myelin-specific autoreac-
tive T cells, which attack the myelin sheath. The Th1
subset of T cells, driven by stimulation with interleukin-
12 (IL-12), composed of p40 and p35 subunits, has trad-
itionally been considered essential for the pathogenesis
of EAE because mice lacking the p40 subunit are resist-
ant to EAE [3, 4]. However, in contrast to mice lacking
the p40 subunit, mice lacking the p35 subunit are highly
susceptible to the induction of EAE, establishing that IL-
12 p70 may not be essential for the development of EAE
[5]. Notably, the p40 subunit of IL-12 is shared by IL-23,
composed of p40 and p19 subunits [6], and mice lacking
either of these subunits are resistant to EAE [7], suggest-
ing that IL-23 is central to the development of EAE. Be-
cause IL-23 is critical for the maintenance, survival, and
proliferation of Th17 cells [8, 9], this T cell subtype has
since been thought to play a pivotal role in the develop-
ment of EAE. Consistent with this idea, mice lacking IL-
17 or RORγt, a transcription factor for Th17 cells, and
mice treated with an IL-17 blocking antibody are less
susceptible to EAE [9–11]. Importantly, autoreactive
Th17 cells preferentially expressing CCR6 have been
shown to trigger the initial inflammation by entering the
CNS through the choroid plexus via a CCR6-CCL20-
dependent mechanism and further infiltrating the CNS
parenchyma by a CCR6-independent mechanism [12]. In
accord with these findings, studies in human patients
have shown that Th17 cells are involved in MS [13, 14].
The C-X-C motif chemokine receptor CXCR3 is mainly
expressed on effector leukocytes, including CD4+ and CD8
+ T cells, natural killer (NK) cells, NKT cells, and subsets of
B cells [15]. CXCR3 and its ligands, CXCL9, CXCL10, and
CXCL11, play a pivotal role in the regulation of inflamma-
tory and infectious diseases, in which CXCR3-bearing ef-
fector leukocytes are recruited to the sites of inflammation
or infection [16]. In particular, CXCR3 and its ligands play
crucial roles in mediating inflammatory diseases of the
CNS [17, 18] and in controlling neurotropic viral infection
in the CNS [19–24]. Although CXCR3 is mainly expressed
on cells of hematopoietic origin, CXCR3 and its ligands
have been detected in the CNS [25–28]. Thus, it is ex-
pected that CXCR3 and its ligands would not only be crit-
ical for the recruitment of effector leukocytes but could
also be important for the regulation of CNS physiology dur-
ing CNS inflammation and infection.
Interestingly, studies on the role of CXCR3 in EAE
have yielded quite controversial findings [29–31]. Two
reports have shown that CXCR3−/− mice are susceptible
to EAE [29, 30]; however, different underlying mecha-
nisms were proposed. Liu et al. showed that CNS tissue
damage is increased in CXCR3−/− mice in association
with decreased production of interferon (IFN)-γ and
iNOS (inducible nitric oxide synthase) [29], whereas
Muller et al. showed that the number of Foxp3+ regula-
tory T cells was reduced in the CNS of CXCR3−/− mice
[30]. In contrast, several studies reported that blockade
or genetic deficiency of either CXCR3 or its primary li-
gands had no impact [31] or detrimental effects on the
manifestations of EAE [31–34]. Thus, the role of CXCR3
in EAE remains elusive. In this study, we demonstrated
that CXCR3−/− mice are more susceptible to EAE. They
also exhibit an increase in CNS-infiltrating Th17 cells
during EAE, which reflects increased expansion of Th17
cells owing to increased numbers of glial cells in the
CNS and an enhanced pro-Th17 cytokine/chemokine
milieu produced by CXCR3-deficient CNS glial cells.
Notably, our study is the first to demonstrate a critical
role of CXCR3 in CNS glial cells rather than in CNS-
infiltrating T cells in the pathogenesis of EAE.
Methods
Mice
The generation of CXCR3−/− mice was described
previously [35]. The mice used in these experiments were
backcrossed to C57BL/6 for ten generations. For adoptive-
transfer EAE experiments, littermates of C57BL/6 wild-
type (WT) or CXCR3−/− mice were used as donors and
Thy1.1+/+C57BL/6 and Thy1.1+/+CXCR3−/− mice were
used as recipients. All mice were bred under specific
pathogen-free conditions at the animal center of the Insti-
tute of Biomedical Sciences (Academia Sinica, Taipei,
Taiwan). All animal experiments were approved by the In-
stitutional Animal Care and Utilization Committee at
Academia Sinica and were performed in accordance with
institutional guidelines.
Cell line
The glioblastoma cell line U87MG was obtained from Dr.
Pang-Hsien Tu (Academia Sinica, Taipei, Taiwan) and cul-
tured in Dulbecco’s modified Eagle medium (DMEM; Life
Technologies, Carlsbad, CA) supplemented with 10 %
fetal bovine serum (FBS; Life Technologies), 2 mM L-glu-
tamine, 1 mM sodium pyruvate, 10 mM HEPES (pH 7.0),
and 0.1 mM nonessential amino acids at 37 °C in a hu-
midified 5 % CO2 atmosphere.
Induction of EAE
Mice (8–12 weeks old) were immunized subcutaneously
in the hind limbs on day 0 with 100 μg of myelin oligo-
dendrocyte glycoprotein (MOG)35–55 peptide (MEVGW
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YRSPFSRVVHLYRNGK; MDBio, Taipei, Taiwan) in
complete Freund’s adjuvant (CFA) containing 400 μg of
heat-killed Mycobacterium tuberculosis H37RA (Sigma-
Aldrich, St. Louis, MO). Two hundred nanograms of
pertussis toxin (PTX) (List Biological Laboratories,
Campbell, CA) was injected intraperitoneally on days 0
and 2. Mice were graded daily on a clinical scale of 0–6:
0, no sign; 0.5, partially flaccid tail; 1, tail paralysis; 2, im-
paired righting reflex or gait; 3, partial hind limb paraly-
sis; 4, total hind limb paralysis; 5, hind limb paralysis
with partial front limb weakness; and 6, moribundity or
death.
H&E and LFB staining
Mice were anesthetized and intracardially perfused with
saline followed by 4 % paraformaldehyde in phosphate-
buffered saline (PBS). Spinal cords were embedded in par-
affin and then cut into 5-μm-thick transverse sections.
Sections were deparaffinized, hydrated, and stained with
hematoxylin and eosin (H&E) and luxol fast blue (LFB).
For LFB staining, sections were incubated with LFB solu-
tion at 60 °C overnight and then washed sequentially with
95 % ethanol, water, 0.1 % lithium carbonate solution,
70 % ethanol, and water. The sections were then dehy-
drated with ethanol, rinsed with xylene, and mounted. In
some experiments, sections stained with LFB were coun-
terstained with cresyl violet.
Confocal microscopy
Sections were deparaffinized and hydrated with an etha-
nol series (100, 95, 90, 80, and 70 %, sequentially). The
sections were then boiled in retrieval solution (Dako,
Glostrup, Denmark) for 40 min and cooled to room
temperature. After blocking with PBS containing 5 % bo-
vine serum albumen (BSA) and 0.2 % Tween-20 at room
temperature for 30 min, sections were incubated at 4 °C
overnight with a primary antibody to Iba1 (Wako,
Osaka, Japan). The sections were then washed and incu-
bated with species-specific secondary antibody conju-
gated with Alexa Fluor 568 (Life Technologies) together
with Alexa Fluor 488-conjugated anti-glial fibrillary
acidic protein (GFAP; clone GA5; eBioscience, San
Diego, CA) at 4 °C overnight. The sections were washed
with PBS, mounted with fluorescence mounting medium
(Dako) containing 1 μg/ml of DAPI (4’,6-diamidino-2-
phenylindole), and observed by confocal microscopy
(LSM 700 system with a Plan Apochromat ×10 objective;
Carl Zeiss, Oberkochen, Germany). Images were ac-
quired with ZEN software (Carl Zeiss), and data were
analyzed using MetaMorph software (SPOT Imaging So-
lutions, Sterling Heights, MI).
To perform immunofluorescence staining of CXCR3
expression on glial cells in the spinal cord, spinal cords
were embedded and frozen in OCT (Sakura, Alphen an
den Rijn, Netherlands). Ten-micrometer transverse sec-
tions were warmed at room temperature for 10 min,
fixed in ice-cold acetone for 5 min, and air-dried for
10 min. Sections were then washed with PBST (0.05 %
Tween-20 in PBS) and blocked with PBST containing
5 % BSA for 1 h. After blocking, sections were stained
with hamster anti-mouse CXCR3 (clone CXCR3-173;
BioLegend, San Diego, CA) along with anti-GFAP-Alexa
Fluor 647 (clone 2E1.E9; BioLegend) for detecting the
expression of CXCR3 on astrocytes or with rabbit anti-
mouse Iba1 (Wako) for detecting the expression of
CXCR3 on microglia. After 4-h incubation, sections for
detecting CXCR3 on microglia were washed with PBST
and further incubated with biotin-conjugated goat anti-
hamster IgG (clone Poly4055; BioLegend) along with
goat anti-rabbit Alexa Fluor 568 (Thermo Fisher Scien-
tific) for 2 h at room temperature followed by washing
with PBST. All sections were then incubated with Alexa
Fluor 488-conjugated streptavidin (BioLegend) for 2 h at
room temperature. Finally, sections were incubated with
0.1 % Suden black (Sigma-Aldrich) for 10 min, washed,
mounted, and inspected using confocal microscopy
(LSM 700 system with a Plan Apochromat ×40 object-
ive). To perform immunofluorescence staining of IL-17
expression in the spinal cord during EAE, frozen sec-
tions were prepared, fixed, blocked as above, and
followed by sequential staining with rat anti-mouse CD4
(BD Bioscience, Franklin Lake, NJ) and goat anti-mouse
IL-17 (Santa Cruz Biotechnology, Dallas, TX), donkey
anti-goat Alexa Fluor 488 (Thermo Fisher Scientific,
Rockford, IL), biotin-conjugated donkey anti-rat IgG
(Abcam, Cambridge, MA), and finally Alexa Fluor 555-
conjugated streptavidin (Thermo Fisher). The sections
were inspected using confocal microscopy (LSM 700
system with a Plan Apochromat ×40 objective).
Th17 polarization and adoptive transfer
For adoptive-transfer EAE experiments, donor mice
were immunized as described above except without in-
jection of PTX. Ten days after immunization, mice were
sacrificed, and splenocytes were harvested and subjected
to Th17-polarizing culture. Cells (4 × 106 cell/ml) were
cultured at 37 °C in a humidified 5 % CO2 atmosphere
for 72 h in RPMI 1640 medium (Life Technologies) sup-
plemented with 10 % FBS (Thermo Scientific, Rockford,
IL); 2 mM L-glutamine; 50 μM 2-mercaptoethanol
(Merck, Whitehouse Station, NJ); 100 U/ml of penicillin
and 100 μg/ml of streptomycin; 10 μg/ml of MOG35–55;
Th17-polarizing cytokines, including IL-6 (20 ng/ml;
R&D Systems, Minneapolis, MN), IL-23 (20 ng/ml; R&D
Systems), and transforming growth factor (TGF)-β
(5 ng/ml; PeproTech, Rocky Hill, NJ); and neutralizing
antibodies against various cytokines (eBioscience), in-
cluding IL-4 (10 μg/ml), IFN-γ (10 μg/ml), and IL-2
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(10 μg/ml). The cultured cells were harvested, and CD4+
T cells were purified using magnetic-activated cell-
sorting (MACS) beads (Miltenyi Biotec, Auburn, CA).
Th17 cells (3 × 105 cells per mouse for analysis of sur-
vival rate; 2 × 105 cells per mouse for cell cycle analyses)
were intravenously injected into recipient mice that had
been irradiated with a dose of 4 Gy. Recipient mice were
immunized with 10 μg of MOG35–55 peptide in CFA
containing 50 μg of M. tuberculosis and received 200 ng
of PTX intraperitoneally on days 0 and day 2. Mice were
monitored daily, and clinical scores were graded.
Isolation of CNS-infiltrating leukocytes
Spinal cords were collected on days 0, 10, and 15
post-immunization for active EAE and on day 12
post-immunization for adoptive-transfer EAE. The
spinal cord was excised, minced, and subjected to en-
zymatic digestion by incubating tissues in 1 ml of di-
gestion buffer containing serum-free RPMI medium
supplemented with 0.5 mg/ml of collagenase IV
(Sigma-Aldrich) and 1000 U/ml of DNase I (Calbio-
tech, Spring Valley, CA) for 30 min at 37 °C. Cells
were washed once with PBS containing 5 % FBS, collected
by centrifugation at 340×g, and resuspended in 5 ml of
30 % Percoll solution (GE Healthcare Life Sciences, Piscat-
away, NJ). The 30 % Percoll homogenate mix was layered
over 70 % Percoll followed by centrifugation at 2000×g for
20 min at room temperature. Leukocytes were collected
from the 30 %/70 % Percoll interface and, after washing
three times with complete medium, were ready for immu-
nostaining and cell cycle experiments.
Flow cytometry analysis
For intracellular cytokine staining, cells were stimulated
with 20 ng/ml of phorbol 12-myristate 13-acetate (PMA;
Sigma-Aldrich) and 1 μM ionomycin (Sigma-Aldrich) in
the presence of 10 μg/ml of brefeldin A (BioLegend) for
4 h at 37 °C. Cells were then harvested, washed with
fluorescence-activated cell-sorting (FACS) buffer (HBSS
containing 1 % FBS and HEPES, pH 7.0), and incubated
with anti-CD16/CD32 (2.4G2, BD Bioscience) at 4 °C for
15 min followed by surface staining with anti-CD4-APC-
Cy7 or anti-CD4-APC (RM4-5; BioLegend) at 4 °C for
15 min. After two washes with PBS, cells were stained
with fixable viability dye conjugated with eFluor 780
(eBioscience) at 4 °C for 15 min, washed with PBS buffer,
and fixed with 2 % paraformaldehyde at 4 °C. After a 1-
h fixation, cells were washed with intracellular staining
(IC) buffer containing 1 % BSA and 0.1 % saponin (Sigma-
Aldrich) in PBS at 4 °C. Cells were then incubated with
2 % normal rat serum (eBioscience) in IC buffer for
30 min followed by intracellular staining with anti-IL-17-
PerCp-Cy5.5 (TC11-18H10.1; BioLegend) and anti-IFN-γ-
PE (XMG1.2; BioLegend) at room temperature for
30 min. After two washes with FACS buffer, cells were
subjected to FACS analysis. For surface staining of CXCR3
expression on U87MG cells, cells were stained with anti-
CXCR3-APC (CXCR3-173; BioLegend) followed by FACS
analysis. FACS analyses were performed using the LSRII
system (BD Biosciences), and data were analyzed using
FlowJo software (Tree Star, Ashland, OR).
Cell cycle analysis of CNS-infiltrating leukocytes
For cell cycle analysis of CNS-infiltrating cells, mice
were intraperitoneally injected with 1 mg of BrdU (BD
Biosciences) on day 11 post-immunization with MOG.
Twenty-four hours after BrdU injection, CNS-infiltrating
leukocytes were isolated, cultured for 4 h, and subjected
to cell cycle analysis using a BrdU Flow Kit according to
the manufacturer’s instructions (BD Biosciences). Briefly,
cells were harvested, immunostained with anti-CD4-
APC-Cy7, washed and fixed with Cytofix/Cytoperm buf-
fer at 4 °C for 30 min, washed with Perm/Wash buffer,
resuspended in Cytoperm Plus buffer at 4 °C for 10 min,
and washed again. Cells were fixed once more with
Cytofix/Cytoperm buffer at room temperature for 5 min
followed by several washes. Cells were then treated with
DNase (300 μg/ml) for 1 h at 37 °C, washed, and stained
with anti-IL-17-PerCp-Cy5.5, anti-IFN-γ-PE, and anti-
BrdU-FITC for 20 min at 37 °C. Finally, cells were
washed, resuspended in 1 ml of FACS buffer containing
7-AAD (7-aminoactinomycin D), and subjected to FACS
analysis.
Generation of primary microglia and astrocytes from
neonatal mice
The cerebral cortex was dissected from a neonatal
mouse (1-day old) brain, placed in HBSS containing
100 U/ml of penicillin and 100 μg/ml of streptomycin,
and mechanically disrupted by gently pipetting. Cells
were cultured in DMEM supplemented with 10 % FBS
(Life Technologies), 2 mM L-glutamine, 100 U/ml of
penicillin, 100 μg/ml of streptomycin, OPI media supple-
ment (1 mM oxaloacetate, 0.45 mM pyruvate, 0.2 U/ml
of insulin; Sigma-Aldrich), and 0.5 ng/ml of granulocyte/
macrophage-colony stimulating factor (GM-CSF; Pepro-
Tech) in a 75T flask coated with poly-L-lysine (Sigma-
Aldrich) at 37 °C in a humidified 5 % CO2 atmosphere.
The medium was completely replaced with fresh
medium on day 1, and half of the medium was replaced
with fresh medium on days 4, 7, and 10. On day 12,
microglia were obtained by vigorously slapping the flask
to dislodge microglia attached to the astrocyte mono-
layer. Adherent astrocytes were subjected to trypsin-
EDTA digestion, washed, and collected. The purity of
microglia and astrocytes was determined by surface
staining with anti-CD11b (clone M1/70; eBioscience) for
microglia and by intracellular staining with anti-GFAP
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(clone GA5; eBioscience) for astrocytes. Both cell prepara-
tions were >90 % pure. Isolated microglia and astrocytes
(2 × 105 cells/ml) were plated in DMEM supplemented
with 10 % FBS, 2 mM L-glutamine, 100 U/ml of penicillin,
100 μg/ml of streptomycin and OPI, and cultured over-
night, followed by incubation with or without lipopolysac-
charide (LPS) (100 ng/ml; Sigma-Aldrich) for 24 h.
Culture supernatants were collected for analysis of cyto-
kines by enzyme-linked immunosorbent assay (ELISA).
ELISA
The levels of IL-23p19 (eBioscience) and CCL20 (R&D
Systems) in culture supernatants were measured by ELISA
according to the manufacturers’ instructions.
RT-PCR
Total RNA was extracted from the spinal cord using the
TRIzol reagent (Life Technologies) according to the
manufacturer’s instructions. Total RNA was reversed
transcribed into complementary DNA (cDNA) using
SuperScript III reverse transcriptase (Life Technologies)
and random hexamer primers according to the manufac-
turer’s instructions. The cDNA was subjected to quanti-
tative real-time reverse transcription polymerase chain
reaction (RT-qPCR) using TaqMan Gene Expression As-
says (Applied Biosystems, Foster City, CA) for analysis
of the target genes, IL-23p19, CCL20, IL-17, GM-CSF,
CXCL9, and CXCL10; GAPDH (glyceraldehyde-3-phos-
phate dehydrogenase) was used as an internal control.
The thermal cycling protocol entailed initial heating at
95 °C for 10 min followed by 40 cycles of 95 °C for
1 min and 60 °C for 1 min. The resultant PCR products
were measured using an ABI prism 7500 Sequence De-
tection System (Applied Biosystems). The levels of target
messenger RNAs (mRNAs), normalized to the level of
GAPDH, were analyzed using the ΔΔCt method.
Western blotting
U87MG cells (106) were serum-starved for 6 h in fasting
medium (DMEM supplemented with 0.5 % BSA, 2 mM
L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES
pH 7.0, and 0.1 mM nonessential amino acids) followed
by treatment with 100 ng/ml of CXCL10 (PeproTech)
prior to stimulation with or without 100 ng/ml of IL-17
(R&D Systems). Cells were lysed in a lysis buffer con-
taining 25 mM Tris (pH 7.4), 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1 % Triton X-100, protease inhibi-
tor cocktail (EMD Millipore, Billerica, MA), and phos-
phatase inhibitor cocktail (Sigma-Aldrich). Proteins in
cell lysates were resolved by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) on 10 %
gels followed by Western blot analysis using antibodies
against extracellular signal-regulated kinase (ERK),
phospho-ERK, IκB, phospho-IκB, NF-κB p65, poly-
(ADP-ribose) polymerase (PARP; all from Cell Signaling
Technology, Beverly, MA), and α-tubulin (Abcam).
Subcellular fractionation
Cells were harvested, washed with PBS, pelleted, and re-
suspended in hypotonic buffer (10 mM HEPES pH 7.9,
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, protease in-
hibitor cocktail) and incubated on ice for 15 min. After
incubation, 10 % NP-40 was added to the cell suspen-
sions (1/16, v/v) and mixed by vortexing for 10 s. The ly-
sates were then centrifuged at 12,000×g at 4 °C for
5 min to pellet nuclei, and supernatants were collected
as the cytoplasmic fraction. The nuclear pellets were
washed twice with hypotonic buffer and then resus-
pended in hypertonic buffer (20 mM HEPES pH 7.9,
1.5 mM MgCl2, 420 mM NaCl, 25 % glycerol, protease
inhibitor cocktail). Nuclear lysates were incubated at 4 °C
for 15 min followed by centrifugation at 12,000×g for
5 min at 4 °C. Supernatants were collected as the nuclear
fraction. Both cytoplasmic and nuclear fractions were sub-
jected to SDS-PAGE followed by Western blot analysis.
Statistical analysis
Data are presented as means ± SEM. Because the sample
size is small (<30 samples) and the data is not normally
distributed evaluated by Shapiro–Wilk test, we used
Mann–Whitney U test to evaluate the significance of dif-
ferences between two experimental results. The Log-rank
test was used for the analysis of survival rates. A P < 0.05
was considered statistically significant.
Results
CXCR3−/− mice develop more severe EAE
To examine the impact of CXCR3 on the development
of EAE, we induced EAE in WT and CXCR3−/− mice
and determined the kinetics of disease onset and sever-
ity. Both WT and CXCR3−/− mice developed a mono-
phasic disease characterized by ascending paralysis from
day 12 to day 15 after immunization followed by a grad-
ual recovery (Fig. 1a). CXCR3−/− mice had slightly earlier
disease onset (day 12) compared with WT mice (day
13.8), and the overall disease development was signifi-
cantly more severe in CXCR3−/− mice than in WT mice
(P < 0.05, Fig. 1a). We further performed LFB staining to
examine demyelinating lesions and leukocyte infiltration
in the spinal cord of WT and CXCR3−/− mice. Equivalent
sections of lumbar spinal cords from WT and CXCR3−/−
were compared, and CXCR3−/− mice exhibited substantial
demyelination accompanied by an increase in inflamma-
tion in the spinal cord compared with WT mice (Fig. 1b).
The comparison of demyelination and inflammation in
serial sections from lumbar spinal cords of WT and
CXCR3−/− mice is also shown in Additional file 1:
Figure S1, and sections of the spinal cords from CXCR3−/−
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mice consistently showed more severe demyelination
and inflammation as compared with WT mice.
CXCR3−/− mice exhibit significantly increased CNS-
infiltrating Th17 cells during EAE
Given that EAE is a T cell-mediated inflammatory disease,
we examined the subsets of infiltrating CD4+ effector T
cells in the spinal cord at the peak of disease (day 15).
Mononuclear cells were isolated from the spinal cords on
day 15 post-immunization and immunostained for surface
CD4 and intracellular IL-17 and IFN-γ by FACS. The gat-
ing strategy of FACS analysis is shown in Fig. 2a. Total
CNS-infiltrating leukocytes were significantly increased in
CXCR3−/−mice compared with WT mice (P < 0.01, Fig. 2b),
as were the total numbers of all CD4+ T cells infiltrating
the spinal cord (P < 0.05, Fig. 2c). The increase in infiltrat-
ing CD4+ cells was further analyzed based on subpopula-
tions. Infiltrating CD4+IFN-γ+ (Th1) cells were comparable
between CXCR3−/− mice and WT mice (Fig. 2d), whereas
infiltrating CD4+IL-17+ (Th17) cells were significantly
increased in CXCR3−/− mice compared with WT mice
(P < 0.001, Fig. 2e). The immunofluorescence staining of
Th17 cells in frozen tissue sections of the spinal cord is
also performed and shown in Additional file 2: Figure S2.
CXCR3−/− mice adoptively transferred with Th17 cells
polarized from CD4+ T cells of MOG-immunized CXCR3−/−
mice are significantly more susceptible to EAE
Having established that infiltrating Th17 cells in the
CNS are increased in CXCR3−/− mice compared with
WT mice during EAE (Fig. 2), we next addressed
whether Th17 cells polarized from CXCR3−/− CD4+ T
cells were more detrimental for EAE development by
performing adoptive-transfer EAE experiments. Donor
WT or CXCR3−/− mice were immunized with MOG,
and splenocytes were collected at the subclinical phase
(10 day post-immunization). Splenocytes were cultured
with MOG under Th17-polarizing conditions followed
by purification of CD4+ T cells. Polarized Th17 cells
from WT or CXCR3−/− mice were adoptively transferred
into irradiated WT or CXCR3−/− recipient mice followed
by immunization with a suboptimal dose of MOG. WT
recipient mice receiving Th17 cells polarized from
CXCR3−/− CD4+ T cells (CXCR3−/−➔WT) showed a
survival rate comparable to that of WT mice receiving
Th17 cells polarized from WT CD4+ T cells (WT➔
WT) (Fig. 3a, left panel). Similarly, CXCR3-/- recipient
mice receiving Th17 cells polarized from CXCR3−/−
CD4+ T cells (CXCR3-/-➔CXCR3−/−) showed a survival
rate comparable to that of CXCR3-/- recipient mice re-
ceiving Th17 cells polarized from WT CD4+ T cells
(WT➔CXCR3−/−) (Fig. 3a, right panel). These results
suggest that Th17 cells polarized from WT or CXCR3−/−
CD4+ T cells may not be responsible for the severity of
disease observed in CXCR3−/− mice. However, we noted
that survival rates were always low in cases where recipi-
ents were CXCR3−/− mice (Fig. 3a, left panel vs. right
panel). Applying another approach for comparing the
survival rate between WT and CXCR3−/− recipient mice,
we found that irradiated CXCR3−/− recipient mice
Fig. 1 CXCR3−/− mice develop more severe EAE. EAE was induced in WT (n = 11) and CXCR3−/− (n = 11) mice by immunizing with
MOG/CFA. a Clinical scores of WT and CXCR3−/− mice at various times after immunization are shown. Data are representative of six independent
experiments (*P < 0.05). b Sections of the lumbar spinal cord (original magnification ×100) collected from WT and CXCR3−/− mice at the peak of
disease (day 15) were fixed and subjected to LFB staining followed by counterstaining with cresyl violet for detection of demyelination (blue) and
inflammation (purple). Arrows indicate infiltrating leukocytes. n stands for the number of mice
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adoptively transferred with Th17 cells polarized from
WT or CXCR3−/− CD4+ T cells always showed signifi-
cantly increased morbidity compared with irradiated
WT recipient mice receiving polarized Th17 cells from
the same origin (P < 0.05; Fig. 3b). Because both WT and
CXCR3−/− mice received identical Th17 cells, the only
difference that could account for the more severe EAE is
the specific CNS microenvironment in the recipient
mice. Taken together, these results demonstrate that Th17
cells polarized from either WT or CXCR3−/− CD4+ T cells
do not significantly contribute to the disease severity of
CXCR3−/− mice; instead, the CNS milieu in CXCR3−/−
mice is mainly responsible. On the basis of these results,
we conclude that CXCR3 expressed on CNS-resident cells
negatively regulates EAE pathogenesis.
CXCR3−/− recipient mice show increased CNS-infiltrating
Th17 cells compared with WT recipient mice in adoptive-
transfer EAE
Given that CXCR3−/− mice show more severe EAE and
significantly increased infiltrating Th17 cells (Fig. 2), and
that disease severity in CXCR3−/− mice is associated with
the CNS milieu (Fig. 3), we next investigated whether
the CNS milieu in CXCR3−/− was favorable for CNS-
infiltrating Th17 cells. To this end, we performed
adoptive-transfer EAE experiments in which Th17 cells
polarized from WT or CXCR3−/− mice were adoptively
transferred into irradiated WT or CXCR3−/− recipient
mice followed by immunization with a suboptimal dose
of MOG. Following transfer of Th17 cells of the same
origin polarized either from WT or CXCR3−/− CD4+ T
cells, CXCR3−/− recipient mice showed a significant in-
crease in total CNS-infiltrating leukocytes (P < 0.01 for
WT➔WT vs. WT➔CXCR3−/− and CXCR3−/−➔WT
vs. CXCR3−/−➔CXCR3−/−; Fig. 4a) and CD4+ T cells (P
< 0.01 for WT➔WT vs. WT➔CXCR3−/− and P < 0.05
for CXCR3−/−➔WT vs. CXCR3-/-➔CXCR3−/−; Fig. 4b)
compared with WT recipient mice. Furthermore, the
total number of CNS-infiltrating Th1 cells was compar-
able (Fig. 4c), whereas Th17 cells were significantly ele-
vated in CXCR3−/− recipient mice compared with WT
recipient mice (P < 0.001 for WT➔WT vs. WT➔
CXCR3−/− and P < 0.0001 for CXCR3−/−➔WT vs.
CXCR3-/-➔CXCR3−/−; Fig. 4d). These results show that
Fig. 2 CNS-infiltrating Th17 cells are significantly elevated in CXCR3−/− mice compared with WT mice. Mononuclear cells were isolated from the
spinal cords of MOG-immunized WT (n = 35) and CXCR3−/− (n = 34) mice at the peak of disease. Total and subpopulations of CNS-infiltrating
lymphocytes were determined by surface staining and intracellular staining using flow cytometry as described in the “Methods” section. a The
gating strategy is shown: a mononuclear cells from spinal cords were gated; b the live mononuclear cells were further gated from total mononuclear
cells shown in a; c CD4+ T cells were further gated from live mononuclear cells shown in b; and d the subpopulation of CD4+IFN-γ+ T cells and CD4
+IL-17+ T cells were identified from CD4+ T cells shown in c. b Total CNS-infiltrating leukocytes. c CNS-infiltrating CD4+ T cells. d CNS-infiltrating CD4
+IFN-γ+ T cells. e CNS-infiltrating CD4+IL-17+ T cells. Each mouse is represented by a symbol. Data shown are from six independent
experiments. *P < 0.05; **P < 0.01; ***P < 0.001
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a CXCR3-deficient CNS milieu indeed promotes better
expansion of Th17 cells, regardless of their origin, than a
WT CNS milieu.
Although WT or CXCR3−/− mice receiving Th17 cells
polarized from CXCR3-/-CD4+ T cells showed a ten-
dency toward an increased number of CNS-infiltrating
Th17 cells compared with mice that received Th17 cells
polarized from WT CD4+ T cells (CXCR3−/−➔WT vs.
WT➔WT and CXCR3−/−➔CXCR3−/− vs. WT➔
CXCR3−/−), this difference did not reach statistical dif-
ference (Fig. 4d). Notably, the rank order of increased
CNS-infiltrating Th17 cells in adoptive-transfer EAE was
CXCR3−/−➔CXCR3−/− >WT➔CXCR3−/− >CXCR3−/−
➔WT >WT➔WT, further supporting the conclusion
that a CXCR3-deficient CNS milieu has a greater impact
on Th17 expansion during EAE than Th17 cells derived
from CXCR3-deficient CD4+ T cells. The gating strategy
for FACS analysis of total lymphocytes, CD4+ T cells,
CD4+IFN-γ+, and CD4+IL-17+ is shown in Additional
file 3: Figure S3
Th17 cells infiltrating the spinal cord of CXCR3−/− mice
show increased proliferation compared to those
infiltrating the spinal cord of WT mice
Since adoptive-transfer EAE experiments showed that
the number of Th17 cells is significantly increased in the
CXCR3-deficient CNS milieu compared with the WT
CNS milieu (Fig. 4), we hypothesized that Th17 cells
would proliferate better in a CXCR3-deficient CNS mi-
lieu. To test this hypothesis, we performed a cell cycle
analysis of infiltrating CD4+ T cells in the spinal cord in
the aforementioned adoptive-transfer EAE experiments
(Fig. 4) by injecting recipient mice with BrdU and har-
vesting CNS-infiltrating cells 24 h later. The CNS-
infiltrating cells were subjected to cell cycle analysis by
immunostaining with fluorochrome-conjugated anti-
BrdU and 7-ADD. As shown in Fig. 5a, a significantly
higher percentage of WT CD4+ T cells were in S phase
when adoptively transferred into CXCR3−/− recipient
mice than into WT recipient mice (P < 0.01 for WT➔
WT vs. WT➔CXCR3−/−; Fig. 5b). Similarly, CXCR3−/−
CD4+ T cells showed a significantly higher percentage of
cells in S phase when adoptively transferred into CXCR3−/−
recipient mice than into WT recipient mice (P < 0.05 for
CXCR3−/−➔WT vs. CXCR3−/−➔CXCR3−/−; Fig. 5b). No
significant difference was observed in the percentages of
cells in G0/G1, G2/M, or apoptosis phases among these
four groups of recipient mice (Fig. 5b). We further analyzed
the number of CD4+IL-17+ T cells in S phase. As expected,
the number of CD4+ IL-17+ T cells in S phase was signifi-
cantly increased in CXCR3−/− recipient mice compared
with WT recipient mice (P < 0.001 for WT➔WT vs. WT
➔CXCR3−/− and CXCR3−/−➔WT vs. CXCR3−/−➔
CXCR3−/−; Fig. 5c). The rank order of the increase in CNS-
infiltrating Th17 cells in adoptive-transfer EAE experiments
(CXCR3−/−➔CXCR3−/− >WT➔CXCR3−/− >CXCR3−/−
➔WT >WT➔WT; Fig. 4d) is consistent with the rank
order of CD4+IL-17+ T cell proliferation (CXCR3-/-➔
CXCR3−/− >WT➔CXCR3−/− >CXCR3−/−➔WT >WT
➔WT; Fig. 5c). These results suggest that the CXCR3-
deficient CNS milieu has a greater impact on the increase
in CNS-infiltrating Th17 cells observed in CXCR3−/− mice
than does the increased proliferative capability of Th17 cells
polarized from CXCR3-deficient CD4+ T cells. The gating
Fig. 3 A CXCR3-deficient CNS milieu is responsible for the higher
susceptibility of CXCR3−/− mice to EAE. Splenocytes isolated from
MOG-immunized WT or CXCR3−/− mice on day 10 post-immunization
were cultured under Th17-polarizing conditions in the presence of
MOG, IL-6, IL-23, and TGF-β for 72 h. Cultured CD4+ T cells were purified
by MACS-positive selection, and 3 × 105 CD4+IL-17+ cells were transferred
into irradiated (4 Gy) WT or CXCR3−/− mice followed by immunization
with a suboptimal dose of MOG/CFA (10 μg/50 μg) and injection of PTX
(200 ng/ml; day 0 and day 2). Four adoptive-transfer EAE experiments
were performed: (1) WT (Th17)→WT, (2) WT (Th17)→ CXCR3−/−, (3)
CXCR3−/− (Th17)→WT, and (4) CXCR3−/− (Th17)→ CXCR3−/−. Survival
rates of recipient WT and CXCR3−/− mice at various times post-
immunization are shown. a Comparison of transfer of polarized Th17
cells with different origins into WT recipient mice (WT→WT vs. CXCR3-/-
→WT, left panel) or CXCR3−/− recipient mice (WT→ CXCR3−/− vs.
CXCR3-/-→ CXCR3−/−, right panel). b Comparison of transfer of
polarized Th17 cells with the same origins into WT or CXCR3−/−
recipient mice (WT→WT vs. WT→ CXCR3−/−, left panel; CXCR3
−/−→WT vs. CXCR3−/−→ CXCR3−/−, right panel). Data shown are
from two independent experiments (12 mice for each adoptive-transfer
EAE group). *P< 0.05; **P< 0.01; ***P< 0.001
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strategy for FACS analysis of cell cycle phase of CD4+ T
cells is shown in Additional file 4: Figure S4.
The results from Figs. 4 and 5 show that the increase
in CNS-infiltrating Th17 cells in CXCR3−/− mice during
EAE is likely attributable to the extrinsic effect of a pro-
Th17 milieu generated by the CXCR3-deficient CNS.
Notably, although CXCR3 mainly regulates effector
lymphocyte trafficking to inflamed tissues, our current
study provides the first demonstration that a CXCR3 de-
ficiency in the CNS has a greater impact on the patho-
genesis of EAE.
Cytokines required for Th17 expansion and recruitment
are significantly increased in the spinal cord in CXCR3−/−
mice compared with WT mice
Having found that a CXCR3-deficient CNS milieu pro-
motes Th17 cell expansion (Figs. 4 and 5), we next ex-
amined whether a CXCR3 deficiency generates a CNS
microenvironment preferential for Th17 proliferation,
survival, maintenance, and recruitment. An analysis of
cytokine gene expression in the spinal cord from MOG-
immunized WT and CXCR3−/− mice on days 0, 10
(preclinical phase), and 14 (peak phase) revealed that
mRNAs for cytokines required for the expansion of
Th17 cells were significantly increased in the spinal cord
of CXCR3−/− mice compared with WT mice at both pre-
clinical (day 10) and peak (day 14) phases (Fig. 6). The
expression levels of cytokine genes IL-6, IL-23p19, GM-
CSF, and IL-17 responsible for the expansion of Th17
cells (Fig. 6a) and chemokine gene CCL20 (Fig. 6b) re-
sponsible for the recruitment of Th17 cells into inflam-
matory sites were significantly elevated in the spinal
cord of CXCR3−/− mice. The levels of mRNAs for the
CXCR3 ligands CXCL9 and CXCL10 were also signifi-
cantly increased (Fig. 6b).
CXCR3-deficient glial cells stimulated with LPS
significantly increase IL-23 and CCL20 secretion
Given that production of pro-Th17 cytokines is in-
creased in the CXCR3-deficient spinal cord (Fig. 6) and
that glial cells, astrocytes and microglia, in CNS paren-
chymal tissues express CXCR3 [26, 28, 36], we further
examined whether glial cells lacking CXCR3 preferen-
tially produced cytokines required for Th17 cell gener-
ation and recruitment during inflammation. Primary
glial cells were isolated from the cortex of neonatal
mouse brains and differentiated into microglia and as-
trocytes. Microglia and astrocytes were stimulated with
lipopolysaccharide (LPS) followed by an analysis of the
secretion of IL-23 and CCL20, which are required for
the expansion and recruitment of Th17 cells, respect-
ively. As shown in Fig. 7, both astrocytes (Fig. 7a) and
microglia (Fig. 7b) differentiated from the CXCR3−/−
brain cortex showed increased levels of IL-23 and
CCL20 compared with those differentiated from WT
mice. Primary glial cells isolated from CXCR3−/− mice
produced greater amounts of cytokines compared with
those isolated from WT mice (Fig. 7), suggesting an in-
trinsic increase in pro-Th17 cytokines in CXCR3-
deficient glial cells.
CXCR3−/− mice exhibit a significant increase in the
number of glial cells in the spinal cord compared with WT
mice during EAE
The levels of cytokines that favor Th17 cell expansion
and recruitment were significantly increased in the
spinal cord of CXCR3−/− mice compared with WT mice
(Fig. 6). This increase could result from enhanced cyto-
kine production by CXCR3-deficient glial cells and/or an
increase in the number of glial cells in the spinal cord of
CXCR3−/− mice during EAE. The pro-Th17 cytokine pro-
duction in CXCR3-deficient glial cells was significantly
Fig. 4 CXCR3−/− recipient mice show increased CNS-infiltrating Th17 cells. Adoptive-transfer EAE was performed as described in Fig. 3, except that
2 × 105 donor CD4+IL-17+ cells were used for adoptive-transfer experiments (WT→WT and WT→ CXCR3−/−, 18 recipient mice for each group;
CXCR3−/−→WT and CXCR3-/-→ CXCR3−/−, 19 recipient mice for each group). Spinal cords were collected from recipient mice on day 12 post-
immunization, and CNS-infiltrating cells were isolated. Different subsets of T cells were identified by surface and intracellular staining using flow
cytometry. a Total CNS-infiltrating leukocytes. b CNS-infiltrating CD4+ T cells. c CNS-infiltrating CD4+IFN-γ+ T cells. d CNS-infiltrating CD4+IL-17+
T cells. Each mouse is represented by a symbol. Data shown are from three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001;
****P < 0.0001. The gating strategy for the FACS analysis of this figure is shown in Additional file 3: Figure S3
Chung and Liao Journal of Neuroinflammation  (2016) 13:76 Page 9 of 17
increased compared to WT glial cells, likely owing to
an intrinsic effect (Fig. 7). We next examined whether
an increase in the number of glial cells in the spinal
cord of CXCR3−/− mice also contributed to the in-
creased cytokine expression in CXCR3−/− mice during
EAE. Spinal cord sections from lumbar (Fig. 8a, b) and
thoracic regions (Fig. 8c, d) of WT and CXCR3−/− mice
were subjected to immunofluorescence staining. Astro-
cytes and microglia were detected using antibodies to
GFAP and Iba1, respectively. Astrocytes were not evi-
dent within gray matter in naïve WT or CXCR3−/− mice
(data not shown). However, the number of astrocytes
(GFAP+) within gray matter was significantly increased
during EAE in both WT and CXCR3−/− mice, but this
increase was greater in CXCR3−/− mice (Fig. 8a, c). Not-
ably, astrocytes within white matter in CXCR3−/− mice be-
came intensively GFAP immunoreactive (Fig. 8a, c),
indicating more severe inflammation in CXCR3−/− mice
compared with WT mice. These results suggest that
astroglial proliferation and hypertrophy in the spinal
cord is significantly greater in CXCR3−/− mice than in
WT mice. Similarly, microglia within white matter
were significantly increased in the spinal cord of
CXCR3−/− mice compared with WT mice (Fig. 8a, c).
The increased number of glial cells in the spinal cord
of CXCR3−/− mice may also contribute to the in-
creased levels of pro-Th17 cytokines/chemokines,
leading to an increase in CNS-infiltrating Th17 cells
and thus to the increased EAE severity in CXCR3−/−
mice. Notably, the increased number of glial cells in
CXCR3−/− mice reflected the severity of the inflam-
mation, as evidenced by increased leukocyte infiltra-
tion (Fig. 8b, d, upper panel) and demyelination
(Fig. 8, d, lower panel) in the spinal cord. Taken to-
gether, these results indicate that the increased pro-
Th17 cytokine production observed in the spinal cord
of CXCR3−/− mice during EAE results from both the
increased number of glial cells in spinal cords (Fig. 8)
and the increased pro-Th17 cytokine production per
glial cell (Fig. 7).
Fig. 5 The CNS milieu of CXCR3−/− mice promotes the proliferation
of Th17 cells. Adoptive-transfer EAE was performed as described in
Fig. 4. Recipient mice were injected with BrdU on day 11 post-
immunization. At 24-h post-injection, the spinal cord was collected
and CNS-infiltrating cells were isolated. The cells were immunostained
with anti-CD4-APC-Cy7 followed by cell cycle analysis by quantification
of cell-incorporated BrdU and total DNA content (7-AAD).
a Representative flow cytometry plots for cell cycle analysis. b The
percentage of CD4+ T cells in the apoptotic phase, G0/G1 phase,
S phase, and G2/M phase of the cell cycle among the four groups.
c The number of IL-17+ cells in CD4+BrdU+ (S phase) are shown
for the four groups. Each group has 13 mice (n = 13). Each
mouse is represented by a symbol. Data shown are from two
independent experiments. **P < 0.01; ***P < 0.001
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CXCR3 is expressed on glial cells and attenuates NF-κB
activation in glioblastoma cells
Our data showed that CXCR3-deficient glial cells
produce increased amounts of cytokines/chemokines
compared with WT glial cells (Figs. 6 and 7). We hy-
pothesized that CXCR3 signaling in glial cells might
negatively regulate cytokine production. If this was the
case, the absence of CXCR3 on glial cells would be pre-
dicted to amplify cytokine production. We first exam-
ined the expression of CXCR3 on glial cells of the spinal
cord during peak of EAE by immunofluorescence stain-
ing. Comparing to isotype control antibody for anti-
CXCR3 shown in Additional file 5: Figure S5, we
found that CXCR3 expression was detected on both as-
trocytes (Fig. 9a) and microglia (Fig. 9b), consisting with
previous reports that glial cells express CXCR3 [25–28].
We then investigated whether CXCR3 signaling in glial
cells was able to regulate cytokine production negatively
using an in vitro experiment with a glioblastoma cell
line, U87MG, which expresses CXCR3 (Fig. 10a). It has
been shown that CXCR3 signaling induces ERK activa-
tion [37, 38], that activated ERK attenuates NF-κB acti-
vation [39–41], and that activated NF-κB is required for
the transcriptional regulation of IL-23p19 and CCL20
[42–45]. We hypothesized that CXCR3 signaling might
reduce production of IL-23 and CCL20 in glial cells
through such a mechanism. Stimulation of U87MG cells
with the CXCR3 ligand CXCL10 induced ERK phos-
phorylation (Fig. 10b), whereas stimulation with IL-17
significantly induced IκB phosphorylation (Fig. 10c, lane
1 vs. lane 2). However, IL-17-induced IκB phosphoryl-
ation was significantly reduced in cells pretreated with
CXCL10 (Fig. 10c, lane 2 vs. lane 3). Similarly, the nu-
clear translocation of NF-κB induced by IL-17 stimula-
tion was also significantly reduced in cells pretreated
with CXCL10 (Fig. 10d, lane 6 vs. lane 7). Furthermore,
pretreatment of cells with PD98059, an ERK inhibitor,
completely prevented CXCR3 signaling from attenuating
IL-17-induced IκB phosphorylation (Fig. 10c, lane 3 vs.
lane 4) and NF-κB activation (Fig. 10d, lane 7 vs. lane 8).
To show that attenuated NF-κB activation mediated by
CXCR3-signaling-induced ERK was indeed able to re-
duce CCL20 production, we measured CCL20 secretion
in the supernatants of cultured U87MG cells. As ex-
pected, the CCL20 secretion induced by IL-17-
stimulated U87MG cells was also significantly reduced
in the presence of CXCL10 (Fig. 10e). These results fur-
ther confirm that the ERK activation elicited by CXCR3
signaling indeed attenuates NF-κB activation, leading to
a subsequent decrease in CCL20 production. Collect-
ively, these results suggest that CXCR3-expressing glial
cells play a role in negatively regulating pro-Th17 cyto-
kine/chemokine production by suppressing NF-κB
activation.
Discussion
Using both active EAE and adoptive-transfer EAE models,
we have demonstrated that CXCR3−/− mice exhibit in-
creased infiltrating Th17 cells in the spinal cord, leading
to the development of more severe EAE. We have further
demonstrated that the increase in CNS-infiltrating Th17
cells in CXCR3-/- mice is attributable to the increased
number of activated glial cells in the CNS as well as in-
creased levels of pro-Th17 cytokines preferentially
Fig. 6 mRNAs for inflammatory chemokines and cytokines required for Th17 cell expansion are increased in CXCR3−/− mice during EAE. WT
(n = 5) and CXCR3−/− (n = 5) mice were immunized with MOG. Spinal cords were collected on days 0, 10, and 14 post-immunization, and total
RNA was extracted and subjected to real-time PCR analysis to determine the mRNA levels for cytokines (a) and chemokines (b). mRNA levels of
target genes, normalized to the level of GAPDH, were analyzed using the ΔΔCt method. n stands for the number of mice. *P < 0.05; **P < 0.01
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produced by CXCR3-deficient glial cells. Moreover, we
identified suppression of NF-κB activation by CXCR3 sig-
naling in glial cells as a possible mechanism underlying
the negative regulation of pro-Th17 cytokines. Notably,
our findings demonstrate a critical role of CXCR3
expressed on glial cells, showing that it prevents the over-
production of Th17 cells by modifying the CNS paren-
chyma microenvironment so as to limit the expansion and
recruitment of Th17 cells during EAE, thus ameliorating
disease severity.
CXCR3 and its ligands (CXCL9, CXCL10, CXCL11)
are thought to govern the recruitment of leukocytes to
the sites of inflammation and infection [15, 46]. One
would expect that a deficiency of CXCR3 would reduce
the recruitment of effector lymphocytes to the sites of
inflammation during EAE, thus conferring resistance to
EAE. On the contrary, two previous studies [29, 30], to-
gether with our current findings, point to CXCR3−/−
mice being more susceptible to EAE than WT mice, sug-
gesting that CXCR3 signaling plays a protective role ra-
ther than a detrimental role in EAE. Interestingly,
although these two previous studies and our study all
show the susceptibility of CXCR3−/− mice to EAE [29, 30],
each has proposed a distinct mechanism. It is known that
Th17 cells are crucial for EAE pathogenesis [9–12].
Consistent with this notion, we found a significant in-
crease in CNS-infiltrating Th17 cells, but not Th1 cells,
in CXCR3−/− mice compared with WT mice (Figs. 2
and 4). Given that ligand-bound CXCR3 promotes IFN-
γ production [47] and that the Th1-associated cytokines
IFN-γ and IL-12 are able to antagonize Th17 cell differ-
entiation and inhibit IL-23-driven proliferation of Th17
cells [48, 49], CXCR3−/− mice would be expected to
have a lower number of Th1 cells and thus fail to effi-
ciently antagonize the proliferation of Th17 cells, lead-
ing to an increase in infiltrating Th17 cells in the spinal
cord. Interestingly, we did not find a reduction in the
number of Th1 cells in CXCR3−/− mice compared with
WT mice; therefore, the increase in CNS-infiltrating
Th17 cells in CXCR3−/− mice cannot be explained by a
reduced number of CNS-infiltrating Th1 cells. Of par-
ticular interest, our study demonstrates that the in-
crease in CNS-infiltrating Th17 cells in CXCR3−/− mice
results from an increase in the number of CNS glial
cells, which preferentially generate a cytokine milieu fa-
vorable for Th17 cell expansion. Our study is the first
to demonstrate the importance of CXCR3 signaling in
glial cells during EAE, establishing that CXCR3
expressed on glial cells negatively regulates Th17 cell
infiltration into the CNS.
Conflicting results regarding the role of CXCR3 and
its ligands in EAE have been reported. Our studies along
with others have demonstrated that CXCR3−/− mice are
susceptible to EAE [29, 30]. However, results showing
resistance to EAE in CXCR3-deficiency mice, or in mice
in which CXCR3 was neutralized, have been reported
[31–34]. These discrepancies might be due to the species
or strain of mice used (rat or B57BL/6 or SJL/J), to the
antigens used for immunization (CNS homogenate,
MOG, myelin basic protein, or myelin proteolipid pro-
tein), to the model used (acute vs. chronic, pharmaco-
logic antagonism, antibody), and to differences in
microbiota (co-housing mice, littermate control). There-
fore, caution should be exercised in interpreting the data
on the role for CXCR3 in EAE; since depending on the
model used, CXCR3 signaling may have either patho-
genic or regulatory effects. The disparate results from
the studies of CXCR3 in EAE are summarized in
Additional file 6: Table S1. Studies of the roles for
CXCR3 in EAE have been focused on the leukocyte re-
cruitment. However, our study is the first to demonstrate
the functional importance of CXCR3 on glial cells nega-
tively regulating Th17 cell expansion during EAE.
Migration of Th17 cells to the CNS has been linked to
the induction of inflammation in MS [50] and EAE [9].
The CCR6-CCL20 axis is important for directing Th17
Fig. 7 IL-23 and CCL20 production are significantly increased in
glial cells derived from the cortex of neonatal CXCR3−/− mouse
brains compared with those from WT mice. The brain cortex was
collected from neonatal mice (day 1), and cells were disaggregated.
Disaggregated cells were cultured in glial cell enrichment medium for
12 days followed by the separation of astrocytes (a) from microglia (b),
as described in the “Methods” section. Astrocytes and microglia were
stimulated with LPS for 24 h, and IL-23p19 and CCL20 levels in
collected culture supernatants were measured by ELISA. Data represent
means ± SEM from eight independent experiments with three
neonatal mice for each experiment. *P < 0.05; **P < 0.01
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cell migration because Th17 cells preferentially express
CCR6, whose ligand is CCL20 [51]. Two recent studies
have investigated the mechanism by which Th17 cells
enter and/or accumulate in the CNS from peripheral
lymphoid organs [12, 52], proposing two different
models. Reboldi et al. showed that Th17 cells enter the
CNS through the choroid plexus, where CCL20 is highly
expressed, and through a CCR6-CCL20-dependent
mechanism and migrate into the subarachnoid space of
the CNS; there, they are activated/proliferate, triggering
the initial inflammation during EAE [12]. Arima et al.
reported that the entry site for Th17 cells into the CNS
during EAE is at dorsal vessels of the fifth lumber cord,
also via the CCR6-CCL20 axis, reflecting the high ex-
pression of CCL20 in these vessels [52]. These two
studies both implicate the importance of CCR6-CCL20
axis in the initial entry of Th17 cells into the CNS. We
found that the levels of CCR6 in Th17 cells polarized
from WT CD4+ T cells and CXCR3−/− CD4+ T cells were
comparable (data not shown); therefore, we anticipate
that the initial entry of Th17 cells into the CNS would
be comparable between WT and CXCR3−/− mice. Fol-
lowing the initial trigger of Th17 cell entry, the infiltrat-
ing Th17 cells then further migrate into the CNS
parenchyma, where they may undergo further expansion
[12, 53, 54]. Given that the CXCR3-deficient spinal cord
produces increased levels of cytokines and chemokines
favorable for the expansion of Th17 cells compared to
the WT spinal cord (Fig. 6) and that Th17 cells in
CXCR3−/− mice show better expansion than that those
Fig. 8 CXCR3−/− mice show elevated numbers of glial cells and increased leukocyte infiltration and demyelination in the spinal cord during EAE.
EAE was induced in WT and CXCR3−/− mice as described in Fig. 1. At 15-days post-immunization, lumbar (a, b) and thoracic (c, d) spinal cords
were collected and subjected to immunofluorescence staining (a, c) and H&E as well as LFB staining (b, d). Immunofluorescence staining for Iba1
(microglial cells) and GFAP (astrocytes) were performed as described in the “Methods” section. Magnified insets highlight the morphology of
activated glial cells in lumbar spinal cords (a) or in thoracic spinal cords (c). Infiltrating leukocytes (b, d; upper panel) and demyelination (b, d;
lower panel) were detected by H&E staining and LFB staining, respectively, in lumbar (b) and thoracic (d) spinal cords. Arrows indicate infiltrating
leukocytes (b, d; upper panel) and demyelination (b, d; lower panel). Data are representative of three independent experiments
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in WT mice (Figs. 4 and 5c), the CXCR3-deficient CNS
parenchyma likely generates a favorable microenviron-
ment for Th17 cell expansion. Based on the studies from
Reboldi et al. [12] and from Arima et al. [52] together
with our study, we propose that the increase in CNS-
infiltrating Th17 cells observed in CXCR3−/− mice dur-
ing EAE is attributable to increased Th17 expansion in
the CNS parenchyma rather than an increase in the ini-
tial entry of Th17 cells into the CNS. Furthermore,
CNS-infiltrating Th17 cells are significantly increased in
CXCR3−/− mice during EAE, likely owing to the in-
creased number of glial cells in the spinal cord of
CXCR3−/− mice (Fig. 8) and to the preferential produc-
tion of pro-Th17 cytokines in CXCR3-deficient glial cells
(Figs. 6 and 7).
Inhibition of NF-κB in astrocytes has been shown to
reduce expression of cytokines and chemokines, result-
ing in decreased expansion and recruitment of effector
leukocytes and subsequent amelioration of EAE [55–57].
NF-κB is an essential transcription factor for the induc-
tion of both IL-23 [42, 43] and CCL20 [45], which are
important for Th17 expansion. Our data showed that
CXCR3-deficient glial cells produce more IL-23 and
CCL20 than WT glia cells (Fig. 7), suggesting the possi-
bility that CXCR3 signaling negatively regulates pro-
Th17 cytokine production in glial cells. The relevance of
this pathway was confirmed by in vitro experiments
showing that NF-κB activation was suppressed by
activated ERK elicited by CXCR3 signaling. Consistent
with these findings, it has been reported that inhibition of
Fig. 9 CXCR3 is expressed on both astrocytes and microglia. Frozen sections of lumbar spinal cord collected from WT and CXCR3−/− mice at the
peak of disease (day 15) were subjected to immunofluorescence staining as described in the “Methods” section. a Double-labeling fluorescent
staining shows CXCR3 on astrocytes. Anti-CXCR3 (green), anti-GFAP (red), DAPI (blue). b Double-labeling fluorescent staining shows CXCR3 on
microglial. Anti-CXCR3 (green), anti-Iba1 (red), DAPI (blue). The arrows indicate co-localization of CXCR3 and glial cell markers. The immunofluorescence
staining with isotype control antibody for anti-CXCR3 is shown in Additional file 5: Figure S5. Data are representative of three independent experiments
Chung and Liao Journal of Neuroinflammation  (2016) 13:76 Page 14 of 17
NF-κB in neuroectodermal cells ameliorates EAE [55, 57].
The detailed molecular mechanism by which CXCR3-
mediated ERK activity attenuates NF-κB activation in glial
cells warrants further investigation.
EAE and MS are complicated diseases involving both
immunological and neurological dysfunctions. The
current study provides evidence that CXCR3 in glial
cells plays a protective role during EAE, demonstrating
that, in addition to its well-known functions in immune
cells, CXCR3 on CNS resident cells also plays an import-
ant physiological role during EAE.
Conclusions
This study identifies a protective role of CXCR3 during
EAE due to its activity on astrocytes and microglia, add-
ing to the receptor’s well-known, more conventional im-
munologic functions. Our data demonstrate that CXCR3
signaling in glial cells attenuates neuroinflammation dur-
ing EAE by limiting pro-Th17 cytokine production,
thereby restraining Th17 cell expansion, reducing CNS-
infiltrating Th17 cells, and subsequently ameliorating
EAE. We further provide a possible underlying mechan-
ism in which ERK activation elicited by CXCR3 signaling
attenuates the activation of NF-κB required for the in-
duction of pro-Th17 cytokines.
Additional files
Additional file 1: Figure S1. CXCR3-/- mice have increased mononuclear
cells infiltrating in the spinal cord as compared with WT mice. The
consecutive sections of the spinal cord (L1) were isolated from MOG-
immunized WT and CXCR3-/- (KO) mice at peak of disease (day 15). LFB
staining was performed for detecting demyelinating. The consecutive
sections of WT1 to WT12 and KO1 to KO12 were cut rostrally after the
sections shown in Fig. 1b. Mononuclear cells infiltrating in white matter
were shown as cresyl violet positive cells (purple, original magnification ×
100). (PDF 1986 kb)
Additional file 2: Figure S2. Th17 cells are detected in the spinal cord
by immunofluorescence assay. a Frozen sections of the spinal cord from
MOG-immunized WT and CXCR3-/- (KO) mice at peak of disease (day 15)
were subjected to immunofluorescence staining with rat anti-mouse CD4
/ biotin conjugateddonkey anti-rat / Alexa 555-conjugated streptavidin
(red) and goat anti-mouse IL-17 / Alexa 488-conjugated donkey anti-goat
(green) followed by counterstaining with DAPI (blue). Arrowheads
indicate IL-17+ cells and arrows indicate CD4+IL-17+ cells (Th17). b Same
procedure in (a) was performed except that goat antimouse IL-17 was
replaced by isotype control antibody. (PDF 375 kb)
Additional file 3: Figure S3. The gating strategy of FACS analysis to
identify subpopulations of CD4+IL-17+ and CD4+IFN-γ+ cells shown in
Fig. 4. Mononuclear cells were isolated from the spinal cord of WT and
CXCR3-/- recipient mice at day 12 post-immunization and subjected to
FACS analysis. Lymphocytes were gated according to forward and side
scatter and then subsequently gated on CD4+ cells. CD4+ cells were
further gated to analyze IFN-γ+ cells (CD4+IFN-γ+, Th1) and IL-17+ cells
(CD4+IL-17+, Th17). Data are representative of three independent
experiments. (PDF 226 kb)
Additional file 4: Figure S4. The gating strategy of FACS analysis to
identify proliferating Th17 cells shown in Fig. 5. Mononuclear cells were
Fig. 10 CXCR3 signaling negatively regulates NF-κB activation induced by IL-17 in a glioblastoma cell line. a U87MG cells were stained with an
anti-CXCR3-APC (solid line) or isotype control (dashed line) antibody followed by FACS analysis. b U87MG cells were serum-starved for 6 h followed
by stimulation with CXCL10 (100 ng/ml). Proteins in whole-cell lysates, prepared at the indicated times, were resolved by SDS-PAGE followed by
immunoblotting with anti-p-ERK and anti-ERK antibodies. c U87MG cells were serum-starved for 6 h and preincubated with or without PD98059
(10 ng/ml) for 15 min followed by incubation with CXCL10 (100 ng/ml) for 60 min. Cells were then stimulated with IL-17 (100 ng/ml) for 15 min
followed by cell lysis. Whole-cell lysates were subjected to SDS-PAGE followed by immunoblotting with antibodies to IκB and phospho-IκB.
d Similar to b except that cells were stimulated with IL-17 for 30 min and cell lysates were fractionated into cytoplasmic and nuclear fractions. Proteins in
whole-cell lysates, cytoplasmic fractions, and nuclear fractions were resolved by SDS-PAGE followed by immunoblotting with antibodies to NF-κB p65,
α-tubulin, and PARP. PARP and α-tubulin were used as markers for the nuclear and the cytoplasmic fractions, respectively. e U87MG cells were cultured
in complete medium containing IL-17 (100 ng/ml) or IL-17 (100 ng/ml) plus CXCL10 (100 ng/ml) for 48 h, after which CCL20 in culture supernatants
was detected by ELISA. Data represent means ± SEM from four independent experiments. *P < 0.05
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isolated from the spinal cord of MOG-immunized WT and CXCR3-/-
recipient mice at day12 post-immunization and subjected to FACS
analysis. Lymphocytes were gated according to forward and side scatter
and then subsequently gated on CD4+ cells. CD4+ cells were further
gated to analyze cell cycle phase distribution. The phases of the cell cycle
of CD4 cells were indicated (G0/G1: BrdU- 7-AAD+; G2/M: BrdU- 7-
AADhigh; S: BrdU+ 7-AADhigh; Apoptosis: BrdU- 7-AADlow). CD4+ cells in S
phase were further gated to analyze IL-17+ cells (CD4+IL-17+, Th17). Data
are representative of two independent experiments. (PDF 183 kb)
Additional file 5: Figure S5. Isotype control antibody for anti-CXCR3 in
Fig. 9. Frozen sections were subjected to immunofluorescence staining as
describe in Fig. 9 except that anti-CXCR3 was replaced with isotype
control antibody. a Astrocytes were marked as GFAP+ cells. b Microglia
were marked as Iba1+ cells. GFAP: red, Iba1: red, isotype control antibody
for anti-CXCR3: green, DAPI: blue. (PDF 981 kb)
Additional file 6: Table S1. The effect of CXCR3 in various studies.
(DOCX 17 kb)
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